#FORMAT=WebAnno TSV 3.3
#T_SP=webanno.custom.ConceptLayer|identifier


Text=The major depressive disorder GWAS-supported variant rs10514299 in TMEM161B-MEF2C predicts putamen activation during reward processing in alcohol dependence Alcohol dependence (AD) frequently co-occurs with major depressive disorder (MDD).
1-1	0-3	The	_
1-2	4-9	major	http://maven.renci.org/NeuroBridge/neurobridge#MajorDepressiveDisorder
1-3	10-20	depressive	_
1-4	21-29	disorder	_
1-5	30-44	GWAS-supported	_
1-6	45-52	variant	_
1-7	53-63	rs10514299	_
1-8	64-66	in	_
1-9	67-81	TMEM161B-MEF2C	_
1-10	82-90	predicts	_
1-11	91-98	putamen	_
1-12	99-109	activation	_
1-13	110-116	during	_
1-14	117-123	reward	_
1-15	124-134	processing	_
1-16	135-137	in	_
1-17	138-145	alcohol	http://maven.renci.org/NeuroBridge/neurobridge#AlcoholAbuse
1-18	146-156	dependence	http://maven.renci.org/NeuroBridge/neurobridge#AlcoholAbuse
1-19	157-164	Alcohol	http://maven.renci.org/NeuroBridge/neurobridge#NondependentAlcoholAbuse
1-20	165-175	dependence	http://maven.renci.org/NeuroBridge/neurobridge#NondependentAlcoholAbuse
1-21	176-177	(	http://maven.renci.org/NeuroBridge/neurobridge#NondependentAlcoholAbuse
1-22	178-180	AD	http://maven.renci.org/NeuroBridge/neurobridge#NondependentAlcoholAbuse
1-23	181-182	)	http://maven.renci.org/NeuroBridge/neurobridge#NondependentAlcoholAbuse
1-24	183-193	frequently	_
1-25	194-203	co-occurs	_
1-26	204-208	with	_
1-27	209-214	major	http://maven.renci.org/NeuroBridge/neurobridge#MajorDepressiveDisorder
1-28	215-225	depressive	http://maven.renci.org/NeuroBridge/neurobridge#MajorDepressiveDisorder
1-29	226-234	disorder	http://maven.renci.org/NeuroBridge/neurobridge#MajorDepressiveDisorder
1-30	235-236	(	http://maven.renci.org/NeuroBridge/neurobridge#MajorDepressiveDisorder
1-31	237-240	MDD	http://maven.renci.org/NeuroBridge/neurobridge#MajorDepressiveDisorder
1-32	241-242	)	http://maven.renci.org/NeuroBridge/neurobridge#MajorDepressiveDisorder
1-33	243-244	.	_

Text=While this comorbidity is associated with an increase in disease burden, worse treatment outcomes, and greater economic costs, the underlying neurobiology remains poorly understood.
2-1	245-250	While	_
2-2	251-255	this	_
2-3	256-267	comorbidity	_
2-4	268-270	is	_
2-5	271-281	associated	_
2-6	282-286	with	_
2-7	287-289	an	_
2-8	290-298	increase	_
2-9	299-301	in	_
2-10	302-309	disease	_
2-11	310-316	burden	_
2-12	317-318	,	_
2-13	319-324	worse	_
2-14	325-334	treatment	_
2-15	335-343	outcomes	_
2-16	344-345	,	_
2-17	346-349	and	_
2-18	350-357	greater	_
2-19	358-366	economic	_
2-20	367-372	costs	_
2-21	373-374	,	_
2-22	375-378	the	_
2-23	379-389	underlying	_
2-24	390-402	neurobiology	_
2-25	403-410	remains	_
2-26	411-417	poorly	_
2-27	418-428	understood	_
2-28	429-430	.	_

Text=A recent large-scale GWAS of MDD has identified a locus in the TMEM161B-MEF2C region (rs10514299) as a novel risk variant; however, the biological relevance of this variant has not yet been studied.
3-1	431-432	A	_
3-2	433-439	recent	_
3-3	440-451	large-scale	_
3-4	452-456	GWAS	_
3-5	457-459	of	_
3-6	460-463	MDD	http://maven.renci.org/NeuroBridge/neurobridge#MajorDepressiveDisorder
3-7	464-467	has	_
3-8	468-478	identified	_
3-9	479-480	a	_
3-10	481-486	locus	_
3-11	487-489	in	_
3-12	490-493	the	_
3-13	494-508	TMEM161B-MEF2C	_
3-14	509-515	region	_
3-15	516-517	(	_
3-16	518-528	rs10514299	_
3-17	529-530	)	_
3-18	531-533	as	_
3-19	534-535	a	_
3-20	536-541	novel	_
3-21	542-546	risk	_
3-22	547-554	variant	_
3-23	555-556	;	_
3-24	557-564	however	_
3-25	565-566	,	_
3-26	567-570	the	_
3-27	571-581	biological	_
3-28	582-591	relevance	_
3-29	592-594	of	_
3-30	595-599	this	_
3-31	600-607	variant	_
3-32	608-611	has	_
3-33	612-615	not	_
3-34	616-619	yet	_
3-35	620-624	been	_
3-36	625-632	studied	_
3-37	633-634	.	_

Text=Given previous reports of disrupted reward processing in both AD and MDD, we hypothesized that rs10514299 would be associated with differences in striatal BOLD responses during reward/loss anticipation in AD.
4-1	635-640	Given	_
4-2	641-649	previous	_
4-3	650-657	reports	_
4-4	658-660	of	_
4-5	661-670	disrupted	_
4-6	671-677	reward	_
4-7	678-688	processing	_
4-8	689-691	in	_
4-9	692-696	both	_
4-10	697-699	AD	http://maven.renci.org/NeuroBridge/neurobridge#AlcoholAbuse
4-11	700-703	and	_
4-12	704-707	MDD	http://maven.renci.org/NeuroBridge/neurobridge#MajorDepressiveDisorder
4-13	708-709	,	_
4-14	710-712	we	_
4-15	713-725	hypothesized	_
4-16	726-730	that	_
4-17	731-741	rs10514299	_
4-18	742-747	would	_
4-19	748-750	be	_
4-20	751-761	associated	_
4-21	762-766	with	_
4-22	767-778	differences	_
4-23	779-781	in	_
4-24	782-790	striatal	_
4-25	791-795	BOLD	_
4-26	796-805	responses	_
4-27	806-812	during	_
4-28	813-824	reward/loss	_
4-29	825-837	anticipation	_
4-30	838-840	in	_
4-31	841-843	AD	http://maven.renci.org/NeuroBridge/neurobridge#AlcoholAbuse
4-32	844-845	.	_

Text=DNA samples from 45 recently detoxified patients with AD and 45 healthy controls (HC) were genotyped for rs10514299.
5-1	846-849	DNA	_
5-2	850-857	samples	_
5-3	858-862	from	_
5-4	863-865	45	_
5-5	866-874	recently	_
5-6	875-885	detoxified	_
5-7	886-894	patients	http://maven.renci.org/NeuroBridge/neurobridge#Schizophrenia
5-8	895-899	with	http://maven.renci.org/NeuroBridge/neurobridge#Schizophrenia
5-9	900-902	AD	http://maven.renci.org/NeuroBridge/neurobridge#Schizophrenia
5-10	903-906	and	_
5-11	907-909	45	_
5-12	910-917	healthy	http://maven.renci.org/NeuroBridge/neurobridge#ControlSubject
5-13	918-926	controls	http://maven.renci.org/NeuroBridge/neurobridge#ControlSubject
5-14	927-928	(	http://maven.renci.org/NeuroBridge/neurobridge#ControlSubject
5-15	929-931	HC	http://maven.renci.org/NeuroBridge/neurobridge#ControlSubject
5-16	932-933	)	http://maven.renci.org/NeuroBridge/neurobridge#ControlSubject
5-17	934-938	were	_
5-18	939-948	genotyped	_
5-19	949-952	for	_
5-20	953-963	rs10514299	_
5-21	964-965	.	_

Text=Participants performed the Monetary Incentive Delay task in a 3-Tesla MRI scanner.
6-1	966-978	Participants	_
6-2	979-988	performed	_
6-3	989-992	the	_
6-4	993-1001	Monetary	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImaging
6-5	1002-1011	Incentive	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImaging
6-6	1012-1017	Delay	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImaging
6-7	1018-1022	task	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImaging
6-8	1023-1025	in	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImaging
6-9	1026-1027	a	_
6-10	1028-1035	3-Tesla	_
6-11	1036-1039	MRI	http://maven.renci.org/NeuroBridge/neurobridge#MagneticResonanceImaging
6-12	1040-1047	scanner	http://maven.renci.org/NeuroBridge/neurobridge#MagneticResonanceImaging
6-13	1048-1049	.	_

Text=Effects of rs10514299 on striatal activation during anticipation of high/low reward/loss were investigated.
7-1	1050-1057	Effects	_
7-2	1058-1060	of	_
7-3	1061-1071	rs10514299	_
7-4	1072-1074	on	_
7-5	1075-1083	striatal	_
7-6	1084-1094	activation	_
7-7	1095-1101	during	_
7-8	1102-1114	anticipation	_
7-9	1115-1117	of	_
7-10	1118-1126	high/low	_
7-11	1127-1138	reward/loss	_
7-12	1139-1143	were	_
7-13	1144-1156	investigated	_
7-14	1157-1158	.	_

Text=Furthermore, we examined associations between rs10514299 and lifetime AD diagnosis in two independent clinical samples [NIAAA: n = 1858 (1123 cases, 735 controls); SAGE: n = 3838 (1848 cases, 1990 controls)], as well as its association with depression severity in a subsample of individuals with a lifetime AD diagnosis (n = 953).
8-1	1159-1170	Furthermore	_
8-2	1171-1172	,	_
8-3	1173-1175	we	_
8-4	1176-1184	examined	_
8-5	1185-1197	associations	_
8-6	1198-1205	between	_
8-7	1206-1216	rs10514299	_
8-8	1217-1220	and	_
8-9	1221-1229	lifetime	_
8-10	1230-1232	AD	http://maven.renci.org/NeuroBridge/neurobridge#DiseaseDiagnosis
8-11	1233-1242	diagnosis	http://maven.renci.org/NeuroBridge/neurobridge#DiseaseDiagnosis
8-12	1243-1245	in	_
8-13	1246-1249	two	_
8-14	1250-1261	independent	_
8-15	1262-1270	clinical	_
8-16	1271-1278	samples	_
8-17	1279-1280	[	_
8-18	1281-1286	NIAAA	_
8-19	1287-1288	:	_
8-20	1289-1290	n	_
8-21	1291-1292	=	_
8-22	1293-1297	1858	_
8-23	1298-1299	(	_
8-24	1300-1304	1123	_
8-25	1305-1310	cases	_
8-26	1311-1312	,	_
8-27	1313-1316	735	_
8-28	1317-1325	controls	_
8-29	1326-1327	)	_
8-30	1328-1329	;	_
8-31	1330-1334	SAGE	_
8-32	1335-1336	:	_
8-33	1337-1338	n	_
8-34	1339-1340	=	_
8-35	1341-1345	3838	_
8-36	1346-1347	(	_
8-37	1348-1352	1848	_
8-38	1353-1358	cases	_
8-39	1359-1360	,	_
8-40	1361-1365	1990	_
8-41	1366-1374	controls	_
8-42	1375-1376	)	_
8-43	1377-1378	]	_
8-44	1379-1380	,	_
8-45	1381-1383	as	_
8-46	1384-1388	well	_
8-47	1389-1391	as	_
8-48	1392-1395	its	_
8-49	1396-1407	association	_
8-50	1408-1412	with	_
8-51	1413-1423	depression	_
8-52	1424-1432	severity	_
8-53	1433-1435	in	_
8-54	1436-1437	a	_
8-55	1438-1447	subsample	_
8-56	1448-1450	of	_
8-57	1451-1462	individuals	_
8-58	1463-1467	with	_
8-59	1468-1469	a	_
8-60	1470-1478	lifetime	_
8-61	1479-1481	AD	http://maven.renci.org/NeuroBridge/neurobridge#DiseaseDiagnosis
8-62	1482-1491	diagnosis	http://maven.renci.org/NeuroBridge/neurobridge#DiseaseDiagnosis
8-63	1492-1493	(	_
8-64	1494-1495	n	_
8-65	1496-1497	=	_
8-66	1498-1501	953	_
8-67	1502-1503	)	_
8-68	1504-1505	.	_

Text=Patients carrying the T allele showed significantly greater putamen activation during anticipation of high reward (p = 0.014), low reward (at trend-level; p = 0.081), high loss (p = 0.024), and low loss (p = 0.046) compared to HCs.
9-1	1506-1514	Patients	_
9-2	1515-1523	carrying	_
9-3	1524-1527	the	_
9-4	1528-1529	T	_
9-5	1530-1536	allele	_
9-6	1537-1543	showed	_
9-7	1544-1557	significantly	_
9-8	1558-1565	greater	_
9-9	1566-1573	putamen	_
9-10	1574-1584	activation	_
9-11	1585-1591	during	_
9-12	1592-1604	anticipation	_
9-13	1605-1607	of	_
9-14	1608-1612	high	_
9-15	1613-1619	reward	_
9-16	1620-1621	(	_
9-17	1622-1623	p	_
9-18	1624-1625	=	_
9-19	1626-1631	0.014	_
9-20	1632-1633	)	_
9-21	1634-1635	,	_
9-22	1636-1639	low	_
9-23	1640-1646	reward	_
9-24	1647-1648	(	_
9-25	1649-1651	at	_
9-26	1652-1663	trend-level	_
9-27	1664-1665	;	_
9-28	1666-1667	p	_
9-29	1668-1669	=	_
9-30	1670-1675	0.081	_
9-31	1676-1677	)	_
9-32	1678-1679	,	_
9-33	1680-1684	high	_
9-34	1685-1689	loss	_
9-35	1690-1691	(	_
9-36	1692-1693	p	_
9-37	1694-1695	=	_
9-38	1696-1701	0.024	_
9-39	1702-1703	)	_
9-40	1704-1705	,	_
9-41	1706-1709	and	_
9-42	1710-1713	low	_
9-43	1714-1718	loss	_
9-44	1719-1720	(	_
9-45	1721-1722	p	_
9-46	1723-1724	=	_
9-47	1725-1730	0.046	_
9-48	1731-1732	)	_
9-49	1733-1741	compared	_
9-50	1742-1744	to	_
9-51	1745-1748	HCs	http://maven.renci.org/NeuroBridge/neurobridge#Thing
9-52	1749-1750	.	_

Text=Association analyses in the NIAAA sample showed a trend-level relationship between rs10514299 and a lifetime AD diagnosis in the European American subgroup (odds ratio = 0.82, p = 0.09).
10-1	1751-1762	Association	_
10-2	1763-1771	analyses	_
10-3	1772-1774	in	_
10-4	1775-1778	the	_
10-5	1779-1784	NIAAA	_
10-6	1785-1791	sample	_
10-7	1792-1798	showed	_
10-8	1799-1800	a	_
10-9	1801-1812	trend-level	_
10-10	1813-1825	relationship	_
10-11	1826-1833	between	_
10-12	1834-1844	rs10514299	_
10-13	1845-1848	and	_
10-14	1849-1850	a	_
10-15	1851-1859	lifetime	_
10-16	1860-1862	AD	_
10-17	1863-1872	diagnosis	_
10-18	1873-1875	in	_
10-19	1876-1879	the	_
10-20	1880-1888	European	_
10-21	1889-1897	American	_
10-22	1898-1906	subgroup	_
10-23	1907-1908	(	_
10-24	1909-1913	odds	_
10-25	1914-1919	ratio	_
10-26	1920-1921	=	_
10-27	1922-1926	0.82	_
10-28	1927-1928	,	_
10-29	1929-1930	p	_
10-30	1931-1932	=	_
10-31	1933-1937	0.09	_
10-32	1938-1939	)	_
10-33	1940-1941	.	_

Text=This finding was not replicated in the SAGE sample.
11-1	1942-1946	This	_
11-2	1947-1954	finding	_
11-3	1955-1958	was	_
11-4	1959-1962	not	_
11-5	1963-1973	replicated	_
11-6	1974-1976	in	_
11-7	1977-1980	the	_
11-8	1981-1985	SAGE	_
11-9	1986-1992	sample	_
11-10	1993-1994	.	_

Text=In the NIAAA sample, the T allele was significantly associated with greater depression symptom severity in individuals with a lifetime AD diagnosis (β = 1.25, p = 0.02); this association was driven by the African American ancestry subgroup (β = 2.11, p = 0.008).
12-1	1995-1997	In	_
12-2	1998-2001	the	_
12-3	2002-2007	NIAAA	_
12-4	2008-2014	sample	_
12-5	2015-2016	,	_
12-6	2017-2020	the	_
12-7	2021-2022	T	_
12-8	2023-2029	allele	_
12-9	2030-2033	was	_
12-10	2034-2047	significantly	_
12-11	2048-2058	associated	_
12-12	2059-2063	with	_
12-13	2064-2071	greater	_
12-14	2072-2082	depression	_
12-15	2083-2090	symptom	_
12-16	2091-2099	severity	_
12-17	2100-2102	in	_
12-18	2103-2114	individuals	http://maven.renci.org/NeuroBridge/neurobridge#AlcoholAbuse
12-19	2115-2119	with	http://maven.renci.org/NeuroBridge/neurobridge#AlcoholAbuse
12-20	2120-2121	a	http://maven.renci.org/NeuroBridge/neurobridge#AlcoholAbuse
12-21	2122-2130	lifetime	http://maven.renci.org/NeuroBridge/neurobridge#AlcoholAbuse
12-22	2131-2133	AD	http://maven.renci.org/NeuroBridge/neurobridge#AlcoholAbuse
12-23	2134-2143	diagnosis	http://maven.renci.org/NeuroBridge/neurobridge#AlcoholAbuse
12-24	2144-2145	(	_
12-25	2146-2147	β	_
12-26	2148-2149	=	_
12-27	2150-2154	1.25	_
12-28	2155-2156	,	_
12-29	2157-2158	p	_
12-30	2159-2160	=	_
12-31	2161-2165	0.02	_
12-32	2166-2167	)	_
12-33	2168-2169	;	_
12-34	2170-2174	this	_
12-35	2175-2186	association	_
12-36	2187-2190	was	_
12-37	2191-2197	driven	_
12-38	2198-2200	by	_
12-39	2201-2204	the	_
12-40	2205-2212	African	_
12-41	2213-2221	American	_
12-42	2222-2230	ancestry	_
12-43	2231-2239	subgroup	_
12-44	2240-2241	(	_
12-45	2242-2243	β	_
12-46	2244-2245	=	_
12-47	2246-2250	2.11	_
12-48	2251-2252	,	_
12-49	2253-2254	p	_
12-50	2255-2256	=	_
12-51	2257-2262	0.008	_
12-52	2263-2264	)	_
12-53	2265-2266	.	_

Text=We show for the first time that the previously identified MDD risk variant rs10514299 in TMEM161B-MEF2C predicts neuronal correlates of reward processing in an AD phenotype, possibly explaining part of the shared pathophysiology and comorbidity between the disorders.
13-1	2267-2269	We	_
13-2	2270-2274	show	_
13-3	2275-2278	for	_
13-4	2279-2282	the	_
13-5	2283-2288	first	_
13-6	2289-2293	time	_
13-7	2294-2298	that	_
13-8	2299-2302	the	_
13-9	2303-2313	previously	_
13-10	2314-2324	identified	_
13-11	2325-2328	MDD	http://maven.renci.org/NeuroBridge/neurobridge#MajorDepressiveDisorder
13-12	2329-2333	risk	_
13-13	2334-2341	variant	_
13-14	2342-2352	rs10514299	_
13-15	2353-2355	in	_
13-16	2356-2370	TMEM161B-MEF2C	_
13-17	2371-2379	predicts	_
13-18	2380-2388	neuronal	_
13-19	2389-2399	correlates	_
13-20	2400-2402	of	_
13-21	2403-2409	reward	_
13-22	2410-2420	processing	_
13-23	2421-2423	in	_
13-24	2424-2426	an	_
13-25	2427-2429	AD	http://maven.renci.org/NeuroBridge/neurobridge#AlcoholAbuse
13-26	2430-2439	phenotype	_
13-27	2440-2441	,	_
13-28	2442-2450	possibly	_
13-29	2451-2461	explaining	_
13-30	2462-2466	part	_
13-31	2467-2469	of	_
13-32	2470-2473	the	_
13-33	2474-2480	shared	_
13-34	2481-2496	pathophysiology	_
13-35	2497-2500	and	_
13-36	2501-2512	comorbidity	_
13-37	2513-2520	between	_
13-38	2521-2524	the	_
13-39	2525-2534	disorders	_
13-40	2535-2536	.	_

Text=Materials and methods Participants The Neuroimaging Sample included 90 participants (45 AD and 45 HC) with a mean age of 39.78 (SD = 11.33; see Table 1).
14-1	2537-2546	Materials	http://maven.renci.org/NeuroBridge/neurobridge#StudyMethod
14-2	2547-2550	and	http://maven.renci.org/NeuroBridge/neurobridge#StudyMethod
14-3	2551-2558	methods	http://maven.renci.org/NeuroBridge/neurobridge#StudyMethod
14-4	2559-2571	Participants	_
14-5	2572-2575	The	_
14-6	2576-2588	Neuroimaging	_
14-7	2589-2595	Sample	_
14-8	2596-2604	included	_
14-9	2605-2607	90	_
14-10	2608-2620	participants	_
14-11	2621-2622	(	_
14-12	2623-2625	45	_
14-13	2626-2628	AD	http://maven.renci.org/NeuroBridge/neurobridge#AlcoholAbuse
14-14	2629-2632	and	_
14-15	2633-2635	45	_
14-16	2636-2638	HC	http://maven.renci.org/NeuroBridge/neurobridge#NoKnownDisorder
14-17	2639-2640	)	_
14-18	2641-2645	with	_
14-19	2646-2647	a	_
14-20	2648-2652	mean	_
14-21	2653-2656	age	_
14-22	2657-2659	of	_
14-23	2660-2665	39.78	_
14-24	2666-2667	(	_
14-25	2668-2670	SD	_
14-26	2671-2672	=	_
14-27	2673-2678	11.33	_
14-28	2679-2680	;	_
14-29	2681-2684	see	_
14-30	2685-2690	Table	_
14-31	2691-2692	1	_
14-32	2693-2694	)	_
14-33	2695-2696	.	_

Text=Prior to study participation, participants in the Neuroimaging and NIAAA Sample provided informed written consent in accordance with the Declaration of Helsinki and as approved by the National Institute on Alcohol Abuse and Alcoholism Review Board.
15-1	2697-2702	Prior	_
15-2	2703-2705	to	_
15-3	2706-2711	study	_
15-4	2712-2725	participation	_
15-5	2726-2727	,	_
15-6	2728-2740	participants	_
15-7	2741-2743	in	_
15-8	2744-2747	the	_
15-9	2748-2760	Neuroimaging	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImaging
15-10	2761-2764	and	_
15-11	2765-2770	NIAAA	http://maven.renci.org/NeuroBridge/neurobridge#Pyromania
15-12	2771-2777	Sample	_
15-13	2778-2786	provided	_
15-14	2787-2795	informed	_
15-15	2796-2803	written	_
15-16	2804-2811	consent	_
15-17	2812-2814	in	_
15-18	2815-2825	accordance	_
15-19	2826-2830	with	_
15-20	2831-2834	the	_
15-21	2835-2846	Declaration	_
15-22	2847-2849	of	_
15-23	2850-2858	Helsinki	_
15-24	2859-2862	and	_
15-25	2863-2865	as	_
15-26	2866-2874	approved	_
15-27	2875-2877	by	_
15-28	2878-2881	the	_
15-29	2882-2890	National	_
15-30	2891-2900	Institute	_
15-31	2901-2903	on	_
15-32	2904-2911	Alcohol	_
15-33	2912-2917	Abuse	_
15-34	2918-2921	and	_
15-35	2922-2932	Alcoholism	_
15-36	2933-2939	Review	_
15-37	2940-2945	Board	_
15-38	2946-2947	.	_

Text=All participants completed the Structured Clinical Interview for DSM-IV-TR Axis I Disorders (SCID-IV).
16-1	2948-2951	All	_
16-2	2952-2964	participants	_
16-3	2965-2974	completed	_
16-4	2975-2978	the	_
16-5	2979-2989	Structured	http://maven.renci.org/NeuroBridge/neurobridge#StructuredClinicalInterviewforDSMDisorders
16-6	2990-2998	Clinical	http://maven.renci.org/NeuroBridge/neurobridge#StructuredClinicalInterviewforDSMDisorders
16-7	2999-3008	Interview	http://maven.renci.org/NeuroBridge/neurobridge#StructuredClinicalInterviewforDSMDisorders
16-8	3009-3012	for	http://maven.renci.org/NeuroBridge/neurobridge#StructuredClinicalInterviewforDSMDisorders
16-9	3013-3022	DSM-IV-TR	http://maven.renci.org/NeuroBridge/neurobridge#StructuredClinicalInterviewforDSMDisorders
16-10	3023-3027	Axis	http://maven.renci.org/NeuroBridge/neurobridge#StructuredClinicalInterviewforDSMDisorders
16-11	3028-3029	I	http://maven.renci.org/NeuroBridge/neurobridge#StructuredClinicalInterviewforDSMDisorders
16-12	3030-3039	Disorders	http://maven.renci.org/NeuroBridge/neurobridge#StructuredClinicalInterviewforDSMDisorders
16-13	3040-3041	(	http://maven.renci.org/NeuroBridge/neurobridge#StructuredClinicalInterviewforDSMDisorders
16-14	3042-3049	SCID-IV	http://maven.renci.org/NeuroBridge/neurobridge#StructuredClinicalInterviewforDSMDisorders
16-15	3050-3051	)	http://maven.renci.org/NeuroBridge/neurobridge#StructuredClinicalInterviewforDSMDisorders
16-16	3052-3053	.	_

Text=Given that DSM-5 criteria for alcohol use disorder are less stringent compared to DSM-IV criteria for AD, all individuals likely fall into the moderate/severe alcohol use disorder categories in DSM-5.
17-1	3054-3059	Given	_
17-2	3060-3064	that	_
17-3	3065-3070	DSM-5	_
17-4	3071-3079	criteria	_
17-5	3080-3083	for	_
17-6	3084-3091	alcohol	http://maven.renci.org/NeuroBridge/neurobridge#AlcoholUseDisordersIdentificationTest
17-7	3092-3095	use	http://maven.renci.org/NeuroBridge/neurobridge#AlcoholUseDisordersIdentificationTest
17-8	3096-3104	disorder	http://maven.renci.org/NeuroBridge/neurobridge#AlcoholUseDisordersIdentificationTest
17-9	3105-3108	are	_
17-10	3109-3113	less	_
17-11	3114-3123	stringent	_
17-12	3124-3132	compared	_
17-13	3133-3135	to	_
17-14	3136-3142	DSM-IV	_
17-15	3143-3151	criteria	_
17-16	3152-3155	for	_
17-17	3156-3158	AD	http://maven.renci.org/NeuroBridge/neurobridge#AlcoholAbuse
17-18	3159-3160	,	_
17-19	3161-3164	all	_
17-20	3165-3176	individuals	_
17-21	3177-3183	likely	_
17-22	3184-3188	fall	_
17-23	3189-3193	into	_
17-24	3194-3197	the	_
17-25	3198-3213	moderate/severe	_
17-26	3214-3221	alcohol	_
17-27	3222-3225	use	http://maven.renci.org/NeuroBridge/neurobridge#DissociativeDrugHarmfulUse
17-28	3226-3234	disorder	http://maven.renci.org/NeuroBridge/neurobridge#DissociativeDrugHarmfulUse
17-29	3235-3245	categories	_
17-30	3246-3248	in	_
17-31	3249-3254	DSM-5	_
17-32	3255-3256	.	_

Text=Exclusion criteria included left-handedness, contraindications for MRI (e.g., claustrophobia or pregnancy), and the presence of any significant medical or neurological diagnoses as assessed by a history and physical exam.
18-1	3257-3266	Exclusion	_
18-2	3267-3275	criteria	_
18-3	3276-3284	included	_
18-4	3285-3300	left-handedness	_
18-5	3301-3302	,	_
18-6	3303-3320	contraindications	_
18-7	3321-3324	for	_
18-8	3325-3328	MRI	_
18-9	3329-3330	(	_
18-10	3331-3335	e.g.	_
18-11	3336-3337	,	_
18-12	3338-3352	claustrophobia	_
18-13	3353-3355	or	_
18-14	3356-3365	pregnancy	_
18-15	3366-3367	)	_
18-16	3368-3369	,	_
18-17	3370-3373	and	_
18-18	3374-3377	the	_
18-19	3378-3386	presence	_
18-20	3387-3389	of	_
18-21	3390-3393	any	_
18-22	3394-3405	significant	_
18-23	3406-3413	medical	_
18-24	3414-3416	or	_
18-25	3417-3429	neurological	_
18-26	3430-3439	diagnoses	_
18-27	3440-3442	as	_
18-28	3443-3451	assessed	_
18-29	3452-3454	by	_
18-30	3455-3456	a	_
18-31	3457-3464	history	_
18-32	3465-3468	and	_
18-33	3469-3477	physical	_
18-34	3478-3482	exam	_
18-35	3483-3484	.	_

Text=Additional exclusion criteria for the HC group included DSM-IV-TR diagnoses of current/past AD, positive urine drug screens, and alcohol breathalyzer readings above zero.
19-1	3485-3495	Additional	_
19-2	3496-3505	exclusion	_
19-3	3506-3514	criteria	_
19-4	3515-3518	for	_
19-5	3519-3522	the	_
19-6	3523-3525	HC	http://maven.renci.org/NeuroBridge/neurobridge#ParallelGroupTrial
19-7	3526-3531	group	http://maven.renci.org/NeuroBridge/neurobridge#ParallelGroupTrial
19-8	3532-3540	included	_
19-9	3541-3550	DSM-IV-TR	_
19-10	3551-3560	diagnoses	_
19-11	3561-3563	of	_
19-12	3564-3576	current/past	_
19-13	3577-3579	AD	_
19-14	3580-3581	,	_
19-15	3582-3590	positive	_
19-16	3591-3596	urine	_
19-17	3597-3601	drug	_
19-18	3602-3609	screens	_
19-19	3610-3611	,	_
19-20	3612-3615	and	_
19-21	3616-3623	alcohol	_
19-22	3624-3636	breathalyzer	_
19-23	3637-3645	readings	_
19-24	3646-3651	above	_
19-25	3652-3656	zero	_
19-26	3657-3658	.	_

Text=FMRI scans were obtained while participants completed a modified version of the MID task where approximately 70% of trials were successful.
20-1	3659-3663	FMRI	_
20-2	3664-3669	scans	_
20-3	3670-3674	were	_
20-4	3675-3683	obtained	_
20-5	3684-3689	while	_
20-6	3690-3702	participants	_
20-7	3703-3712	completed	_
20-8	3713-3714	a	_
20-9	3715-3723	modified	_
20-10	3724-3731	version	_
20-11	3732-3734	of	_
20-12	3735-3738	the	_
20-13	3739-3742	MID	http://maven.renci.org/NeuroBridge/neurobridge#BackTaskTest
20-14	3743-3747	task	http://maven.renci.org/NeuroBridge/neurobridge#BackTaskTest
20-15	3748-3753	where	_
20-16	3754-3767	approximately	_
20-17	3768-3770	70	_
20-18	3771-3772	%	_
20-19	3773-3775	of	_
20-20	3776-3782	trials	_
20-21	3783-3787	were	_
20-22	3788-3798	successful	_
20-23	3799-3800	.	_

Text=Participants were not on any psychotropic medications on the day of the scan and there were no alcohol abstainers among the HC group.
21-1	3801-3813	Participants	_
21-2	3814-3818	were	_
21-3	3819-3822	not	_
21-4	3823-3825	on	_
21-5	3826-3829	any	_
21-6	3830-3842	psychotropic	_
21-7	3843-3854	medications	_
21-8	3855-3857	on	_
21-9	3858-3861	the	_
21-10	3862-3865	day	_
21-11	3866-3868	of	_
21-12	3869-3872	the	_
21-13	3873-3877	scan	_
21-14	3878-3881	and	_
21-15	3882-3887	there	_
21-16	3888-3892	were	_
21-17	3893-3895	no	_
21-18	3896-3903	alcohol	_
21-19	3904-3914	abstainers	_
21-20	3915-3920	among	_
21-21	3921-3924	the	_
21-22	3925-3927	HC	http://maven.renci.org/NeuroBridge/neurobridge#ParallelGroupTrial
21-23	3928-3933	group	http://maven.renci.org/NeuroBridge/neurobridge#ParallelGroupTrial
21-24	3934-3935	.	_

Text=DNA samples were obtained from all participants for genotyping.
22-1	3936-3939	DNA	_
22-2	3940-3947	samples	_
22-3	3948-3952	were	_
22-4	3953-3961	obtained	_
22-5	3962-3966	from	_
22-6	3967-3970	all	_
22-7	3971-3983	participants	_
22-8	3984-3987	for	_
22-9	3988-3998	genotyping	_
22-10	3999-4000	.	_

Text=The NIAAA Sample consisted of 1123 individuals with a DSM-IV-TR diagnosis of AD and 735 HCs who enrolled in research studies at the National Institute on Alcohol Abuse and Alcoholism at the National Institutes of Health Clinical Center in Bethesda, MD (see Table 2).
23-1	4001-4004	The	_
23-2	4005-4010	NIAAA	_
23-3	4011-4017	Sample	_
23-4	4018-4027	consisted	_
23-5	4028-4030	of	_
23-6	4031-4035	1123	_
23-7	4036-4047	individuals	_
23-8	4048-4052	with	_
23-9	4053-4054	a	_
23-10	4055-4064	DSM-IV-TR	http://maven.renci.org/NeuroBridge/neurobridge#StructuredClinicalInterviewforDSMDisorders
23-11	4065-4074	diagnosis	http://maven.renci.org/NeuroBridge/neurobridge#StructuredClinicalInterviewforDSMDisorders
23-12	4075-4077	of	http://maven.renci.org/NeuroBridge/neurobridge#StructuredClinicalInterviewforDSMDisorders
23-13	4078-4080	AD	http://maven.renci.org/NeuroBridge/neurobridge#AlcoholAbuse
23-14	4081-4084	and	_
23-15	4085-4088	735	_
23-16	4089-4092	HCs	http://maven.renci.org/NeuroBridge/neurobridge#Thing
23-17	4093-4096	who	_
23-18	4097-4105	enrolled	_
23-19	4106-4108	in	_
23-20	4109-4117	research	_
23-21	4118-4125	studies	_
23-22	4126-4128	at	_
23-23	4129-4132	the	_
23-24	4133-4141	National	_
23-25	4142-4151	Institute	_
23-26	4152-4154	on	_
23-27	4155-4162	Alcohol	_
23-28	4163-4168	Abuse	_
23-29	4169-4172	and	_
23-30	4173-4183	Alcoholism	_
23-31	4184-4186	at	_
23-32	4187-4190	the	_
23-33	4191-4199	National	_
23-34	4200-4210	Institutes	_
23-35	4211-4213	of	_
23-36	4214-4220	Health	_
23-37	4221-4229	Clinical	_
23-38	4230-4236	Center	_
23-39	4237-4239	in	_
23-40	4240-4248	Bethesda	_
23-41	4249-4250	,	_
23-42	4251-4253	MD	_
23-43	4254-4255	(	_
23-44	4256-4259	see	_
23-45	4260-4265	Table	_
23-46	4266-4267	2	_
23-47	4268-4269	)	_
23-48	4270-4271	.	_

Text=531 individuals with AD and 411 controls were of European American (EA) descent.
24-1	4272-4275	531	_
24-2	4276-4287	individuals	http://maven.renci.org/NeuroBridge/neurobridge#AlcoholAbuse
24-3	4288-4292	with	http://maven.renci.org/NeuroBridge/neurobridge#AlcoholAbuse
24-4	4293-4295	AD	http://maven.renci.org/NeuroBridge/neurobridge#AlcoholAbuse
24-5	4296-4299	and	_
24-6	4300-4303	411	_
24-7	4304-4312	controls	http://maven.renci.org/NeuroBridge/neurobridge#NoKnownDisorder
24-8	4313-4317	were	_
24-9	4318-4320	of	_
24-10	4321-4329	European	_
24-11	4330-4338	American	_
24-12	4339-4340	(	_
24-13	4341-4343	EA	_
24-14	4344-4345	)	_
24-15	4346-4353	descent	_
24-16	4354-4355	.	_

Text=A total of 507 individuals with AD and 232 controls were of African American (AA) descent.
25-1	4356-4357	A	_
25-2	4358-4363	total	_
25-3	4364-4366	of	_
25-4	4367-4370	507	_
25-5	4371-4382	individuals	http://maven.renci.org/NeuroBridge/neurobridge#AlcoholAbuse
25-6	4383-4387	with	http://maven.renci.org/NeuroBridge/neurobridge#AlcoholAbuse
25-7	4388-4390	AD	http://maven.renci.org/NeuroBridge/neurobridge#AlcoholAbuse
25-8	4391-4394	and	_
25-9	4395-4398	232	_
25-10	4399-4407	controls	http://maven.renci.org/NeuroBridge/neurobridge#NoKnownDisorder
25-11	4408-4412	were	_
25-12	4413-4415	of	_
25-13	4416-4423	African	_
25-14	4424-4432	American	_
25-15	4433-4434	(	_
25-16	4435-4437	AA	_
25-17	4438-4439	)	http://maven.renci.org/NeuroBridge/neurobridge#Thing
25-18	4440-4447	descent	_
25-19	4448-4449	.	_

Text=All participants provided blood samples for genotyping.
26-1	4450-4453	All	_
26-2	4454-4466	participants	_
26-3	4467-4475	provided	_
26-4	4476-4481	blood	_
26-5	4482-4489	samples	_
26-6	4490-4493	for	_
26-7	4494-4504	genotyping	_
26-8	4505-4506	.	_

Text=The SAGE was funded by the National Human Genome Research Institute as part of the Gene Environment Association Studies (GENEVA) that consisted of three major studies of addictive disorders: The Collaborative Study on the Genetics of Alcoholism (COGA), the Family Study of Cocaine Dependence (FSCD), and the Collaborative Genetic Study of Nicotine Dependence (COGEND).
27-1	4507-4510	The	_
27-2	4511-4515	SAGE	_
27-3	4516-4519	was	_
27-4	4520-4526	funded	_
27-5	4527-4529	by	_
27-6	4530-4533	the	_
27-7	4534-4542	National	_
27-8	4543-4548	Human	_
27-9	4549-4555	Genome	_
27-10	4556-4564	Research	_
27-11	4565-4574	Institute	_
27-12	4575-4577	as	_
27-13	4578-4582	part	_
27-14	4583-4585	of	_
27-15	4586-4589	the	_
27-16	4590-4594	Gene	_
27-17	4595-4606	Environment	_
27-18	4607-4618	Association	_
27-19	4619-4626	Studies	_
27-20	4627-4628	(	_
27-21	4629-4635	GENEVA	_
27-22	4636-4637	)	_
27-23	4638-4642	that	_
27-24	4643-4652	consisted	_
27-25	4653-4655	of	_
27-26	4656-4661	three	_
27-27	4662-4667	major	_
27-28	4668-4675	studies	_
27-29	4676-4678	of	_
27-30	4679-4688	addictive	_
27-31	4689-4698	disorders	_
27-32	4699-4700	:	_
27-33	4701-4704	The	_
27-34	4705-4718	Collaborative	_
27-35	4719-4724	Study	_
27-36	4725-4727	on	_
27-37	4728-4731	the	_
27-38	4732-4740	Genetics	_
27-39	4741-4743	of	_
27-40	4744-4754	Alcoholism	_
27-41	4755-4756	(	_
27-42	4757-4761	COGA	_
27-43	4762-4763	)	_
27-44	4764-4765	,	_
27-45	4766-4769	the	_
27-46	4770-4776	Family	_
27-47	4777-4782	Study	http://maven.renci.org/NeuroBridge/neurobridge#StudySubject
27-48	4783-4785	of	_
27-49	4786-4793	Cocaine	_
27-50	4794-4804	Dependence	http://maven.renci.org/NeuroBridge/neurobridge#PolysubstanceDependence
27-51	4805-4806	(	_
27-52	4807-4811	FSCD	_
27-53	4812-4813	)	_
27-54	4814-4815	,	_
27-55	4816-4819	and	_
27-56	4820-4823	the	_
27-57	4824-4837	Collaborative	_
27-58	4838-4845	Genetic	_
27-59	4846-4851	Study	http://maven.renci.org/NeuroBridge/neurobridge#StudySubject
27-60	4852-4854	of	_
27-61	4855-4863	Nicotine	_
27-62	4864-4874	Dependence	http://maven.renci.org/NeuroBridge/neurobridge#PolysubstanceDependence
27-63	4875-4876	(	_
27-64	4877-4883	COGEND	_
27-65	4884-4885	)	_
27-66	4886-4887	.	_

Text=The accession number of dbGaP is phs000092.v1.p1.
28-1	4888-4891	The	_
28-2	4892-4901	accession	_
28-3	4902-4908	number	_
28-4	4909-4911	of	_
28-5	4912-4917	dbGaP	_
28-6	4918-4920	is	_
28-7	4921-4936	phs000092.v1.p1	_
28-8	4937-4938	.	_

Text=The EA subgroup of the SAGE Sample consisted of 1162 cases (mean age = 38.2 (9.94); 62% male) and 1346 controls (mean age 38.6 (9.44); 30.3% male).
29-1	4939-4942	The	_
29-2	4943-4945	EA	_
29-3	4946-4954	subgroup	_
29-4	4955-4957	of	_
29-5	4958-4961	the	_
29-6	4962-4966	SAGE	http://maven.renci.org/NeuroBridge/neurobridge#Age
29-7	4967-4973	Sample	_
29-8	4974-4983	consisted	_
29-9	4984-4986	of	_
29-10	4987-4991	1162	_
29-11	4992-4997	cases	_
29-12	4998-4999	(	_
29-13	5000-5004	mean	_
29-14	5005-5008	age	_
29-15	5009-5010	=	_
29-16	5011-5015	38.2	_
29-17	5016-5017	(	_
29-18	5018-5022	9.94	_
29-19	5023-5024	)	_
29-20	5025-5026	;	_
29-21	5027-5029	62	_
29-22	5030-5031	%	_
29-23	5032-5036	male	_
29-24	5037-5038	)	_
29-25	5039-5042	and	_
29-26	5043-5047	1346	_
29-27	5048-5056	controls	http://maven.renci.org/NeuroBridge/neurobridge#NoKnownDisorder
29-28	5057-5058	(	_
29-29	5059-5063	mean	_
29-30	5064-5067	age	_
29-31	5068-5072	38.6	_
29-32	5073-5074	(	_
29-33	5075-5079	9.44	_
29-34	5080-5081	)	_
29-35	5082-5083	;	_
29-36	5084-5088	30.3	_
29-37	5089-5090	%	_
29-38	5091-5095	male	_
29-39	5096-5097	)	_
29-40	5098-5099	.	_

Text=The AA subgroup consisted of 686 cases (mean age = 40.3 (7.7); 61% male) and 644 controls (mean age = 39.6 (7.2); 36% male).
30-1	5100-5103	The	_
30-2	5104-5106	AA	http://maven.renci.org/NeuroBridge/neurobridge#Thing
30-3	5107-5115	subgroup	_
30-4	5116-5125	consisted	_
30-5	5126-5128	of	_
30-6	5129-5132	686	_
30-7	5133-5138	cases	_
30-8	5139-5140	(	_
30-9	5141-5145	mean	_
30-10	5146-5149	age	_
30-11	5150-5151	=	_
30-12	5152-5156	40.3	_
30-13	5157-5158	(	_
30-14	5159-5162	7.7	_
30-15	5163-5164	)	_
30-16	5165-5166	;	_
30-17	5167-5169	61	_
30-18	5170-5171	%	_
30-19	5172-5176	male	_
30-20	5177-5178	)	_
30-21	5179-5182	and	_
30-22	5183-5186	644	_
30-23	5187-5195	controls	http://maven.renci.org/NeuroBridge/neurobridge#NoKnownDisorder
30-24	5196-5197	(	_
30-25	5198-5202	mean	_
30-26	5203-5206	age	_
30-27	5207-5208	=	_
30-28	5209-5213	39.6	_
30-29	5214-5215	(	_
30-30	5216-5219	7.2	_
30-31	5220-5221	)	_
30-32	5222-5223	;	_
30-33	5224-5226	36	_
30-34	5227-5228	%	_
30-35	5229-5233	male	_
30-36	5234-5235	)	_
30-37	5236-5237	.	_

Text=All cases met lifetime DSM-IV criteria for AD, and were excluded if they had schizophrenia or any other psychotic illness.
31-1	5238-5241	All	_
31-2	5242-5247	cases	_
31-3	5248-5251	met	_
31-4	5252-5260	lifetime	_
31-5	5261-5267	DSM-IV	_
31-6	5268-5276	criteria	_
31-7	5277-5280	for	_
31-8	5281-5283	AD	http://maven.renci.org/NeuroBridge/neurobridge#AlcoholAbuse
31-9	5284-5285	,	_
31-10	5286-5289	and	_
31-11	5290-5294	were	_
31-12	5295-5303	excluded	_
31-13	5304-5306	if	_
31-14	5307-5311	they	_
31-15	5312-5315	had	_
31-16	5316-5329	schizophrenia	_
31-17	5330-5332	or	_
31-18	5333-5336	any	_
31-19	5337-5342	other	_
31-20	5343-5352	psychotic	_
31-21	5353-5360	illness	_
31-22	5361-5362	.	_

Text=Controls were defined as individuals who had been exposed to alcohol, but had not met lifetime criteria for AD or other illicit substances.
32-1	5363-5371	Controls	_
32-2	5372-5376	were	_
32-3	5377-5384	defined	_
32-4	5385-5387	as	_
32-5	5388-5399	individuals	_
32-6	5400-5403	who	_
32-7	5404-5407	had	_
32-8	5408-5412	been	_
32-9	5413-5420	exposed	_
32-10	5421-5423	to	_
32-11	5424-5431	alcohol	_
32-12	5432-5433	,	_
32-13	5434-5437	but	_
32-14	5438-5441	had	_
32-15	5442-5445	not	_
32-16	5446-5449	met	_
32-17	5450-5458	lifetime	_
32-18	5459-5467	criteria	_
32-19	5468-5471	for	_
32-20	5472-5474	AD	http://maven.renci.org/NeuroBridge/neurobridge#AlcoholAbuse
32-21	5475-5477	or	_
32-22	5478-5483	other	_
32-23	5484-5491	illicit	_
32-24	5492-5502	substances	_
32-25	5503-5504	.	_

Text=Experimental paradigm Participants completed a modified version of the MID task, which required a fast button response to a target to win or avoid losing money.
33-1	5505-5517	Experimental	_
33-2	5518-5526	paradigm	_
33-3	5527-5539	Participants	_
33-4	5540-5549	completed	_
33-5	5550-5551	a	_
33-6	5552-5560	modified	_
33-7	5561-5568	version	_
33-8	5569-5571	of	_
33-9	5572-5575	the	_
33-10	5576-5579	MID	http://maven.renci.org/NeuroBridge/neurobridge#BackTaskTest
33-11	5580-5584	task	http://maven.renci.org/NeuroBridge/neurobridge#BackTaskTest
33-12	5585-5586	,	_
33-13	5587-5592	which	_
33-14	5593-5601	required	_
33-15	5602-5603	a	_
33-16	5604-5608	fast	_
33-17	5609-5615	button	_
33-18	5616-5624	response	_
33-19	5625-5627	to	_
33-20	5628-5629	a	_
33-21	5630-5636	target	_
33-22	5637-5639	to	_
33-23	5640-5643	win	_
33-24	5644-5646	or	_
33-25	5647-5652	avoid	_
33-26	5653-5659	losing	_
33-27	5660-5665	money	_
33-28	5666-5667	.	_

Text=A trial started with a crosshair for fixation, then a 2-second presentation of a cue (a shape indicating the type of trial: reward, loss, or neutral).
34-1	5668-5669	A	_
34-2	5670-5675	trial	_
34-3	5676-5683	started	_
34-4	5684-5688	with	_
34-5	5689-5690	a	_
34-6	5691-5700	crosshair	_
34-7	5701-5704	for	_
34-8	5705-5713	fixation	_
34-9	5714-5715	,	_
34-10	5716-5720	then	_
34-11	5721-5722	a	_
34-12	5723-5731	2-second	_
34-13	5732-5744	presentation	_
34-14	5745-5747	of	_
34-15	5748-5749	a	_
34-16	5750-5753	cue	_
34-17	5754-5755	(	_
34-18	5756-5757	a	_
34-19	5758-5763	shape	_
34-20	5764-5774	indicating	_
34-21	5775-5778	the	_
34-22	5779-5783	type	_
34-23	5784-5786	of	_
34-24	5787-5792	trial	_
34-25	5793-5794	:	_
34-26	5795-5801	reward	_
34-27	5802-5803	,	_
34-28	5804-5808	loss	_
34-29	5809-5810	,	_
34-30	5811-5813	or	_
34-31	5814-5821	neutral	_
34-32	5822-5823	)	_
34-33	5824-5825	.	_

Text=After a delay screen of variable duration (between 0.75 and 1.75 s) the target was presented (a white-filled square to which the participants were trained to respond to).
35-1	5826-5831	After	_
35-2	5832-5833	a	_
35-3	5834-5839	delay	_
35-4	5840-5846	screen	_
35-5	5847-5849	of	_
35-6	5850-5858	variable	_
35-7	5859-5867	duration	_
35-8	5868-5869	(	_
35-9	5870-5877	between	_
35-10	5878-5882	0.75	_
35-11	5883-5886	and	_
35-12	5887-5891	1.75	_
35-13	5892-5893	s	_
35-14	5894-5895	)	_
35-15	5896-5899	the	_
35-16	5900-5906	target	_
35-17	5907-5910	was	_
35-18	5911-5920	presented	_
35-19	5921-5922	(	_
35-20	5923-5924	a	_
35-21	5925-5937	white-filled	_
35-22	5938-5944	square	_
35-23	5945-5947	to	_
35-24	5948-5953	which	_
35-25	5954-5957	the	_
35-26	5958-5970	participants	_
35-27	5971-5975	were	_
35-28	5976-5983	trained	_
35-29	5984-5986	to	_
35-30	5987-5994	respond	_
35-31	5995-5997	to	_
35-32	5998-5999	)	_
35-33	6000-6001	.	_

Text=Next, another delay screen of variable duration (between 0.75 and 3 s) was presented before the feedback screen appeared.
36-1	6002-6006	Next	_
36-2	6007-6008	,	_
36-3	6009-6016	another	_
36-4	6017-6022	delay	_
36-5	6023-6029	screen	_
36-6	6030-6032	of	_
36-7	6033-6041	variable	_
36-8	6042-6050	duration	_
36-9	6051-6052	(	_
36-10	6053-6060	between	_
36-11	6061-6065	0.75	_
36-12	6066-6069	and	_
36-13	6070-6071	3	_
36-14	6072-6073	s	_
36-15	6074-6075	)	_
36-16	6076-6079	was	_
36-17	6080-6089	presented	_
36-18	6090-6096	before	_
36-19	6097-6100	the	_
36-20	6101-6109	feedback	_
36-21	6110-6116	screen	_
36-22	6117-6125	appeared	_
36-23	6126-6127	.	_

Text=The feedback screen showed the amount that was won or lost in the previous trial, which represented if the participant had successfully pressed the button in time to win or avoid losing the target amount.
37-1	6128-6131	The	_
37-2	6132-6140	feedback	_
37-3	6141-6147	screen	_
37-4	6148-6154	showed	_
37-5	6155-6158	the	_
37-6	6159-6165	amount	_
37-7	6166-6170	that	_
37-8	6171-6174	was	_
37-9	6175-6178	won	_
37-10	6179-6181	or	_
37-11	6182-6186	lost	_
37-12	6187-6189	in	_
37-13	6190-6193	the	_
37-14	6194-6202	previous	_
37-15	6203-6208	trial	_
37-16	6209-6210	,	_
37-17	6211-6216	which	_
37-18	6217-6228	represented	_
37-19	6229-6231	if	_
37-20	6232-6235	the	_
37-21	6236-6247	participant	_
37-22	6248-6251	had	_
37-23	6252-6264	successfully	_
37-24	6265-6272	pressed	_
37-25	6273-6276	the	_
37-26	6277-6283	button	_
37-27	6284-6286	in	_
37-28	6287-6291	time	_
37-29	6292-6294	to	_
37-30	6295-6298	win	_
37-31	6299-6301	or	_
37-32	6302-6307	avoid	_
37-33	6308-6314	losing	_
37-34	6315-6318	the	_
37-35	6319-6325	target	_
37-36	6326-6332	amount	_
37-37	6333-6334	.	_

Text=The total amount of money accumulated up to that point was also presented on the feedback screen.
38-1	6335-6338	The	_
38-2	6339-6344	total	_
38-3	6345-6351	amount	_
38-4	6352-6354	of	_
38-5	6355-6360	money	_
38-6	6361-6372	accumulated	_
38-7	6373-6375	up	_
38-8	6376-6378	to	_
38-9	6379-6383	that	_
38-10	6384-6389	point	_
38-11	6390-6393	was	_
38-12	6394-6398	also	_
38-13	6399-6408	presented	_
38-14	6409-6411	on	_
38-15	6412-6415	the	_
38-16	6416-6424	feedback	_
38-17	6425-6431	screen	_
38-18	6432-6433	.	_

Text=After practicing outside of the scanner and being informed that gains/losses during the task would be reflected in their final payment, each subject completed a 12-minute fMRI session of the MID task.
39-1	6434-6439	After	_
39-2	6440-6450	practicing	_
39-3	6451-6458	outside	_
39-4	6459-6461	of	_
39-5	6462-6465	the	_
39-6	6466-6473	scanner	_
39-7	6474-6477	and	_
39-8	6478-6483	being	_
39-9	6484-6492	informed	_
39-10	6493-6497	that	_
39-11	6498-6510	gains/losses	_
39-12	6511-6517	during	_
39-13	6518-6521	the	_
39-14	6522-6526	task	_
39-15	6527-6532	would	_
39-16	6533-6535	be	_
39-17	6536-6545	reflected	_
39-18	6546-6548	in	_
39-19	6549-6554	their	_
39-20	6555-6560	final	_
39-21	6561-6568	payment	_
39-22	6569-6570	,	_
39-23	6571-6575	each	_
39-24	6576-6583	subject	_
39-25	6584-6593	completed	_
39-26	6594-6595	a	_
39-27	6596-6605	12-minute	_
39-28	6606-6610	fMRI	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImaging
39-29	6611-6618	session	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImaging
39-30	6619-6621	of	_
39-31	6622-6625	the	_
39-32	6626-6629	MID	http://maven.renci.org/NeuroBridge/neurobridge#BackTaskTest
39-33	6630-6634	task	http://maven.renci.org/NeuroBridge/neurobridge#BackTaskTest
39-34	6635-6636	.	_

Text=Five different cues were presented thirty times, each representing a different trial condition; neutral (no reward/no loss), low loss, high loss, low reward, and high reward.
40-1	6637-6641	Five	_
40-2	6642-6651	different	_
40-3	6652-6656	cues	_
40-4	6657-6661	were	_
40-5	6662-6671	presented	_
40-6	6672-6678	thirty	_
40-7	6679-6684	times	_
40-8	6685-6686	,	_
40-9	6687-6691	each	_
40-10	6692-6704	representing	_
40-11	6705-6706	a	_
40-12	6707-6716	different	_
40-13	6717-6722	trial	_
40-14	6723-6732	condition	_
40-15	6733-6734	;	_
40-16	6735-6742	neutral	_
40-17	6743-6744	(	_
40-18	6745-6747	no	_
40-19	6748-6757	reward/no	_
40-20	6758-6762	loss	_
40-21	6763-6764	)	_
40-22	6765-6766	,	_
40-23	6767-6770	low	_
40-24	6771-6775	loss	_
40-25	6776-6777	,	_
40-26	6778-6782	high	_
40-27	6783-6787	loss	_
40-28	6788-6789	,	_
40-29	6790-6793	low	_
40-30	6794-6800	reward	_
40-31	6801-6802	,	_
40-32	6803-6806	and	_
40-33	6807-6811	high	_
40-34	6812-6818	reward	_
40-35	6819-6820	.	_

Text=MRI data acquisition and preprocessing A Siemens 3 T Skyra scanner was used to collect whole-brain echo-planar imaging functional (36 axial slices, 4 mm slice thickness, 64 × 64 matrix and repetition time of 2000 ms) and MPRGE structural data.
41-1	6821-6824	MRI	http://maven.renci.org/NeuroBridge/neurobridge#MagneticResonanceImaging
41-2	6825-6829	data	_
41-3	6830-6841	acquisition	_
41-4	6842-6845	and	_
41-5	6846-6859	preprocessing	_
41-6	6860-6861	A	_
41-7	6862-6869	Siemens	_
41-8	6870-6871	3	http://maven.renci.org/NeuroBridge/neurobridge#2Level
41-9	6872-6873	T	http://maven.renci.org/NeuroBridge/neurobridge#2Level
41-10	6874-6879	Skyra	http://maven.renci.org/NeuroBridge/neurobridge#2Level
41-11	6880-6887	scanner	_
41-12	6888-6891	was	_
41-13	6892-6896	used	_
41-14	6897-6899	to	_
41-15	6900-6907	collect	_
41-16	6908-6919	whole-brain	_
41-17	6920-6931	echo-planar	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalImagingProtocol
41-18	6932-6939	imaging	_
41-19	6940-6950	functional	_
41-20	6951-6952	(	_
41-21	6953-6955	36	_
41-22	6956-6961	axial	_
41-23	6962-6968	slices	_
41-24	6969-6970	,	_
41-25	6971-6972	4	_
41-26	6973-6975	mm	_
41-27	6976-6981	slice	_
41-28	6982-6991	thickness	_
41-29	6992-6993	,	_
41-30	6994-6996	64	_
41-31	6997-6998	×	_
41-32	6999-7001	64	_
41-33	7002-7008	matrix	_
41-34	7009-7012	and	_
41-35	7013-7023	repetition	_
41-36	7024-7028	time	_
41-37	7029-7031	of	_
41-38	7032-7036	2000	_
41-39	7037-7039	ms	_
41-40	7040-7041	)	_
41-41	7042-7045	and	_
41-42	7046-7051	MPRGE	http://maven.renci.org/NeuroBridge/neurobridge#Asperger'sDisorder
41-43	7052-7062	structural	_
41-44	7063-7067	data	_
41-45	7068-7069	.	_

Text=Preprocessing and analysis was performed using AFNI software package.
42-1	7070-7083	Preprocessing	_
42-2	7084-7087	and	_
42-3	7088-7096	analysis	_
42-4	7097-7100	was	_
42-5	7101-7110	performed	_
42-6	7111-7116	using	_
42-7	7117-7121	AFNI	_
42-8	7122-7130	software	_
42-9	7131-7138	package	_
42-10	7139-7140	.	_

Text=Large transients removal was performed before slice-time correction, then nuisance variables were de-trended, including the six parameter estimates for head motion.
43-1	7141-7146	Large	_
43-2	7147-7157	transients	_
43-3	7158-7165	removal	_
43-4	7166-7169	was	_
43-5	7170-7179	performed	_
43-6	7180-7186	before	_
43-7	7187-7197	slice-time	_
43-8	7198-7208	correction	_
43-9	7209-7210	,	_
43-10	7211-7215	then	_
43-11	7216-7224	nuisance	_
43-12	7225-7234	variables	_
43-13	7235-7239	were	_
43-14	7240-7250	de-trended	_
43-15	7251-7252	,	_
43-16	7253-7262	including	_
43-17	7263-7266	the	_
43-18	7267-7270	six	_
43-19	7271-7280	parameter	_
43-20	7281-7290	estimates	_
43-21	7291-7294	for	_
43-22	7295-7299	head	_
43-23	7300-7306	motion	_
43-24	7307-7308	.	_

Text=No participants had any condition censored more than 20% (motion higher than 0.3 mm was censored out), a criterion to be excluded from the analysis.
44-1	7309-7311	No	_
44-2	7312-7324	participants	_
44-3	7325-7328	had	_
44-4	7329-7332	any	_
44-5	7333-7342	condition	_
44-6	7343-7351	censored	_
44-7	7352-7356	more	_
44-8	7357-7361	than	_
44-9	7362-7364	20	_
44-10	7365-7366	%	_
44-11	7367-7368	(	_
44-12	7369-7375	motion	_
44-13	7376-7382	higher	_
44-14	7383-7387	than	_
44-15	7388-7391	0.3	_
44-16	7392-7394	mm	_
44-17	7395-7398	was	_
44-18	7399-7407	censored	_
44-19	7408-7411	out	_
44-20	7412-7413	)	_
44-21	7414-7415	,	_
44-22	7416-7417	a	_
44-23	7418-7427	criterion	_
44-24	7428-7430	to	_
44-25	7431-7433	be	_
44-26	7434-7442	excluded	_
44-27	7443-7447	from	_
44-28	7448-7451	the	_
44-29	7452-7460	analysis	_
44-30	7461-7462	.	_

Text=Images were then coregistered to the individual structural image, resampled (2-mm isotropic), smoothed (4-mm full-width-half-maximum Gaussian kernel), normalized by the mean signal intensity in each voxel to reflect percent signal change, and finally transformed into the standardized.
45-1	7463-7469	Images	_
45-2	7470-7474	were	_
45-3	7475-7479	then	_
45-4	7480-7492	coregistered	_
45-5	7493-7495	to	_
45-6	7496-7499	the	_
45-7	7500-7510	individual	_
45-8	7511-7521	structural	_
45-9	7522-7527	image	_
45-10	7528-7529	,	_
45-11	7530-7539	resampled	_
45-12	7540-7541	(	_
45-13	7542-7546	2-mm	_
45-14	7547-7556	isotropic	_
45-15	7557-7558	)	_
45-16	7559-7560	,	_
45-17	7561-7569	smoothed	_
45-18	7570-7571	(	_
45-19	7572-7576	4-mm	_
45-20	7577-7600	full-width-half-maximum	_
45-21	7601-7609	Gaussian	_
45-22	7610-7616	kernel	_
45-23	7617-7618	)	_
45-24	7619-7620	,	_
45-25	7621-7631	normalized	_
45-26	7632-7634	by	_
45-27	7635-7638	the	_
45-28	7639-7643	mean	_
45-29	7644-7650	signal	_
45-30	7651-7660	intensity	_
45-31	7661-7663	in	_
45-32	7664-7668	each	_
45-33	7669-7674	voxel	_
45-34	7675-7677	to	_
45-35	7678-7685	reflect	_
45-36	7686-7693	percent	_
45-37	7694-7700	signal	_
45-38	7701-7707	change	_
45-39	7708-7709	,	_
45-40	7710-7713	and	_
45-41	7714-7721	finally	_
45-42	7722-7733	transformed	_
45-43	7734-7738	into	_
45-44	7739-7742	the	_
45-45	7743-7755	standardized	_
45-46	7756-7757	.	_

Text=BOLD fMRI data and ROI analysis Single-subject level analysis was performed using AFNI.
46-1	7758-7762	BOLD	_
46-2	7763-7767	fMRI	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalMagneticResonanceImaging
46-3	7768-7772	data	_
46-4	7773-7776	and	_
46-5	7777-7780	ROI	_
46-6	7781-7789	analysis	_
46-7	7790-7804	Single-subject	_
46-8	7805-7810	level	_
46-9	7811-7819	analysis	_
46-10	7820-7823	was	_
46-11	7824-7833	performed	_
46-12	7834-7839	using	_
46-13	7840-7844	AFNI	_
46-14	7845-7846	.	_

Text=Then, using ROI masks of the bilateral caudate, putamen, and nucleus accumbens, generated with AFNI DrawDataset plugins and following previously published literature and subtracting all nuances effects (such as pre-motor activations), except reward/loss response, we computed average percent signal change (beta weights) of the following comparisons: high reward> neutral, low reward> neutral, high loss> neutral, low loss> neutral.
47-1	7847-7851	Then	_
47-2	7852-7853	,	_
47-3	7854-7859	using	_
47-4	7860-7863	ROI	_
47-5	7864-7869	masks	_
47-6	7870-7872	of	_
47-7	7873-7876	the	_
47-8	7877-7886	bilateral	_
47-9	7887-7894	caudate	_
47-10	7895-7896	,	_
47-11	7897-7904	putamen	_
47-12	7905-7906	,	_
47-13	7907-7910	and	_
47-14	7911-7918	nucleus	_
47-15	7919-7928	accumbens	_
47-16	7929-7930	,	_
47-17	7931-7940	generated	_
47-18	7941-7945	with	_
47-19	7946-7950	AFNI	_
47-20	7951-7962	DrawDataset	_
47-21	7963-7970	plugins	_
47-22	7971-7974	and	_
47-23	7975-7984	following	_
47-24	7985-7995	previously	_
47-25	7996-8005	published	_
47-26	8006-8016	literature	_
47-27	8017-8020	and	_
47-28	8021-8032	subtracting	_
47-29	8033-8036	all	_
47-30	8037-8044	nuances	_
47-31	8045-8052	effects	_
47-32	8053-8054	(	_
47-33	8055-8059	such	_
47-34	8060-8062	as	_
47-35	8063-8072	pre-motor	_
47-36	8073-8084	activations	_
47-37	8085-8086	)	_
47-38	8087-8088	,	_
47-39	8089-8095	except	_
47-40	8096-8107	reward/loss	_
47-41	8108-8116	response	_
47-42	8117-8118	,	_
47-43	8119-8121	we	_
47-44	8122-8130	computed	_
47-45	8131-8138	average	_
47-46	8139-8146	percent	_
47-47	8147-8153	signal	_
47-48	8154-8160	change	_
47-49	8161-8162	(	_
47-50	8163-8167	beta	_
47-51	8168-8175	weights	_
47-52	8176-8177	)	_
47-53	8178-8180	of	_
47-54	8181-8184	the	_
47-55	8185-8194	following	_
47-56	8195-8206	comparisons	_
47-57	8207-8208	:	_
47-58	8209-8213	high	_
47-59	8214-8220	reward	_
47-60	8221-8222	>	_
47-61	8223-8230	neutral	_
47-62	8231-8232	,	_
47-63	8233-8236	low	_
47-64	8237-8243	reward	_
47-65	8244-8245	>	_
47-66	8246-8253	neutral	_
47-67	8254-8255	,	_
47-68	8256-8260	high	_
47-69	8261-8265	loss	_
47-70	8266-8267	>	_
47-71	8268-8275	neutral	_
47-72	8276-8277	,	_
47-73	8278-8281	low	_
47-74	8282-8286	loss	_
47-75	8287-8288	>	_
47-76	8289-8296	neutral	_
47-77	8297-8298	.	_

Text=For simplification purposes, we refer to these as high reward, low reward, high loss, and low loss, respectively.
48-1	8299-8302	For	_
48-2	8303-8317	simplification	_
48-3	8318-8326	purposes	_
48-4	8327-8328	,	_
48-5	8329-8331	we	_
48-6	8332-8337	refer	_
48-7	8338-8340	to	_
48-8	8341-8346	these	_
48-9	8347-8349	as	_
48-10	8350-8354	high	_
48-11	8355-8361	reward	_
48-12	8362-8363	,	_
48-13	8364-8367	low	_
48-14	8368-8374	reward	_
48-15	8375-8376	,	_
48-16	8377-8381	high	_
48-17	8382-8386	loss	_
48-18	8387-8388	,	_
48-19	8389-8392	and	_
48-20	8393-8396	low	_
48-21	8397-8401	loss	_
48-22	8402-8403	,	_
48-23	8404-8416	respectively	_
48-24	8417-8418	.	_

Text=Genotyping NIAAA Sample Large-scale genotyping was performed at the NIAAA Laboratory of Neurogenetics using the Illumina OmniExpress BeadChip (Illumina, San Diego, CA).
49-1	8419-8429	Genotyping	_
49-2	8430-8435	NIAAA	_
49-3	8436-8442	Sample	_
49-4	8443-8454	Large-scale	_
49-5	8455-8465	genotyping	_
49-6	8466-8469	was	_
49-7	8470-8479	performed	_
49-8	8480-8482	at	_
49-9	8483-8486	the	_
49-10	8487-8492	NIAAA	_
49-11	8493-8503	Laboratory	_
49-12	8504-8506	of	_
49-13	8507-8520	Neurogenetics	_
49-14	8521-8526	using	_
49-15	8527-8530	the	_
49-16	8531-8539	Illumina	_
49-17	8540-8551	OmniExpress	_
49-18	8552-8560	BeadChip	_
49-19	8561-8562	(	_
49-20	8563-8571	Illumina	_
49-21	8572-8573	,	_
49-22	8574-8577	San	_
49-23	8578-8583	Diego	_
49-24	8584-8585	,	_
49-25	8586-8588	CA	_
49-26	8589-8590	)	_
49-27	8591-8592	.	_

Text=Data for the SNP rs10514299 located within the TMEM161B-AS1 gene cluster was extracted from the larger array.
50-1	8593-8597	Data	_
50-2	8598-8601	for	_
50-3	8602-8605	the	_
50-4	8606-8609	SNP	_
50-5	8610-8620	rs10514299	_
50-6	8621-8628	located	_
50-7	8629-8635	within	_
50-8	8636-8639	the	_
50-9	8640-8652	TMEM161B-AS1	_
50-10	8653-8657	gene	_
50-11	8658-8665	cluster	_
50-12	8666-8669	was	_
50-13	8670-8679	extracted	_
50-14	8680-8684	from	_
50-15	8685-8688	the	_
50-16	8689-8695	larger	_
50-17	8696-8701	array	_
50-18	8702-8703	.	_

Text=Ancestry informative markers (AIMs; n = 2500) were extracted from the Illumina array to calculate ancestral proportions for all study participants.
51-1	8704-8712	Ancestry	_
51-2	8713-8724	informative	_
51-3	8725-8732	markers	_
51-4	8733-8734	(	_
51-5	8735-8739	AIMs	_
51-6	8740-8741	;	_
51-7	8742-8743	n	_
51-8	8744-8745	=	_
51-9	8746-8750	2500	_
51-10	8751-8752	)	_
51-11	8753-8757	were	_
51-12	8758-8767	extracted	_
51-13	8768-8772	from	_
51-14	8773-8776	the	_
51-15	8777-8785	Illumina	_
51-16	8786-8791	array	_
51-17	8792-8794	to	_
51-18	8795-8804	calculate	_
51-19	8805-8814	ancestral	_
51-20	8815-8826	proportions	_
51-21	8827-8830	for	_
51-22	8831-8834	all	_
51-23	8835-8840	study	_
51-24	8841-8853	participants	_
51-25	8854-8855	.	_

Text=Using methods described previously for an AIM panel including 186 markers, which were not available for the current data set, the ancestry assessment identified 6 ethnic factors (Africa, Europe, Asia, Far East Asia, Oceania, and Americas).
52-1	8856-8861	Using	_
52-2	8862-8869	methods	_
52-3	8870-8879	described	_
52-4	8880-8890	previously	_
52-5	8891-8894	for	_
52-6	8895-8897	an	_
52-7	8898-8901	AIM	_
52-8	8902-8907	panel	_
52-9	8908-8917	including	_
52-10	8918-8921	186	_
52-11	8922-8929	markers	_
52-12	8930-8931	,	_
52-13	8932-8937	which	_
52-14	8938-8942	were	_
52-15	8943-8946	not	_
52-16	8947-8956	available	_
52-17	8957-8960	for	_
52-18	8961-8964	the	_
52-19	8965-8972	current	_
52-20	8973-8977	data	_
52-21	8978-8981	set	_
52-22	8982-8983	,	_
52-23	8984-8987	the	_
52-24	8988-8996	ancestry	_
52-25	8997-9007	assessment	_
52-26	9008-9018	identified	_
52-27	9019-9020	6	_
52-28	9021-9027	ethnic	_
52-29	9028-9035	factors	_
52-30	9036-9037	(	_
52-31	9038-9044	Africa	_
52-32	9045-9046	,	_
52-33	9047-9053	Europe	_
52-34	9054-9055	,	_
52-35	9056-9060	Asia	_
52-36	9061-9062	,	_
52-37	9063-9066	Far	_
52-38	9067-9071	East	_
52-39	9072-9076	Asia	_
52-40	9077-9078	,	_
52-41	9079-9086	Oceania	_
52-42	9087-9088	,	_
52-43	9089-9092	and	_
52-44	9093-9101	Americas	_
52-45	9102-9103	)	_
52-46	9104-9105	.	_

Text=SAGE Sample Whole-genome genotyping was completed using the Illumina Human-1M platform (Illumina Inc., San Diego, CA).
53-1	9106-9110	SAGE	_
53-2	9111-9117	Sample	_
53-3	9118-9130	Whole-genome	_
53-4	9131-9141	genotyping	_
53-5	9142-9145	was	_
53-6	9146-9155	completed	_
53-7	9156-9161	using	_
53-8	9162-9165	the	_
53-9	9166-9174	Illumina	_
53-10	9175-9183	Human-1M	_
53-11	9184-9192	platform	_
53-12	9193-9194	(	_
53-13	9195-9203	Illumina	_
53-14	9204-9208	Inc.	_
53-15	9209-9210	,	_
53-16	9211-9214	San	_
53-17	9215-9220	Diego	_
53-18	9221-9222	,	_
53-19	9223-9225	CA	_
53-20	9226-9227	)	_
53-21	9228-9229	.	_

Text=The 190 HapMap samples (48 HapMap control samples, 55 CEU, 55 YUR, 13 CHB, and 17 JPT) were genotyped in the same platform and population stratification analyses were performed using principal component analysis.
54-1	9230-9233	The	_
54-2	9234-9237	190	_
54-3	9238-9244	HapMap	_
54-4	9245-9252	samples	_
54-5	9253-9254	(	_
54-6	9255-9257	48	_
54-7	9258-9264	HapMap	_
54-8	9265-9272	control	_
54-9	9273-9280	samples	_
54-10	9281-9282	,	_
54-11	9283-9285	55	_
54-12	9286-9289	CEU	_
54-13	9290-9291	,	_
54-14	9292-9294	55	_
54-15	9295-9298	YUR	_
54-16	9299-9300	,	_
54-17	9301-9303	13	_
54-18	9304-9307	CHB	_
54-19	9308-9309	,	_
54-20	9310-9313	and	_
54-21	9314-9316	17	_
54-22	9317-9320	JPT	_
54-23	9321-9322	)	_
54-24	9323-9327	were	_
54-25	9328-9337	genotyped	_
54-26	9338-9340	in	_
54-27	9341-9344	the	_
54-28	9345-9349	same	_
54-29	9350-9358	platform	_
54-30	9359-9362	and	_
54-31	9363-9373	population	_
54-32	9374-9388	stratification	_
54-33	9389-9397	analyses	_
54-34	9398-9402	were	_
54-35	9403-9412	performed	_
54-36	9413-9418	using	_
54-37	9419-9428	principal	_
54-38	9429-9438	component	_
54-39	9439-9447	analysis	_
54-40	9448-9449	.	_

Text=After a series of quality control procedures (p value of Hardy-Weinberg equilibrium (HWE) <10e-5, missing rate by SNP> 2%, missing rate by individual> 2%, minor allele frequency <1%, sex inconsistency), there were 1162 case and 1346 control samples in the EA subgroup and 686 case and 644 control samples in AA subgroup.
55-1	9450-9455	After	_
55-2	9456-9457	a	_
55-3	9458-9464	series	_
55-4	9465-9467	of	_
55-5	9468-9475	quality	_
55-6	9476-9483	control	_
55-7	9484-9494	procedures	_
55-8	9495-9496	(	_
55-9	9497-9498	p	_
55-10	9499-9504	value	_
55-11	9505-9507	of	_
55-12	9508-9522	Hardy-Weinberg	_
55-13	9523-9534	equilibrium	_
55-14	9535-9536	(	_
55-15	9537-9540	HWE	_
55-16	9541-9542	)	_
55-17	9543-9544	<	_
55-18	9545-9550	10e-5	_
55-19	9551-9552	,	_
55-20	9553-9560	missing	_
55-21	9561-9565	rate	_
55-22	9566-9568	by	_
55-23	9569-9572	SNP	_
55-24	9573-9574	>	_
55-25	9575-9576	2	_
55-26	9577-9578	%	_
55-27	9579-9580	,	_
55-28	9581-9588	missing	_
55-29	9589-9593	rate	_
55-30	9594-9596	by	_
55-31	9597-9607	individual	_
55-32	9608-9609	>	_
55-33	9610-9611	2	_
55-34	9612-9613	%	_
55-35	9614-9615	,	_
55-36	9616-9621	minor	_
55-37	9622-9628	allele	_
55-38	9629-9638	frequency	_
55-39	9639-9640	<	_
55-40	9641-9642	1	_
55-41	9643-9644	%	_
55-42	9645-9646	,	_
55-43	9647-9650	sex	_
55-44	9651-9664	inconsistency	_
55-45	9665-9666	)	_
55-46	9667-9668	,	_
55-47	9669-9674	there	_
55-48	9675-9679	were	_
55-49	9680-9684	1162	_
55-50	9685-9689	case	_
55-51	9690-9693	and	_
55-52	9694-9698	1346	_
55-53	9699-9706	control	_
55-54	9707-9714	samples	_
55-55	9715-9717	in	_
55-56	9718-9721	the	_
55-57	9722-9724	EA	_
55-58	9725-9733	subgroup	_
55-59	9734-9737	and	_
55-60	9738-9741	686	_
55-61	9742-9746	case	_
55-62	9747-9750	and	_
55-63	9751-9754	644	_
55-64	9755-9762	control	_
55-65	9763-9770	samples	_
55-66	9771-9773	in	_
55-67	9774-9776	AA	_
55-68	9777-9785	subgroup	_
55-69	9786-9787	.	_

Text=Two population stratification scores (PSS) calculated based on principal component analysis were used for statistical analyses.
56-1	9788-9791	Two	_
56-2	9792-9802	population	_
56-3	9803-9817	stratification	_
56-4	9818-9824	scores	_
56-5	9825-9826	(	_
56-6	9827-9830	PSS	_
56-7	9831-9832	)	_
56-8	9833-9843	calculated	_
56-9	9844-9849	based	_
56-10	9850-9852	on	_
56-11	9853-9862	principal	_
56-12	9863-9872	component	_
56-13	9873-9881	analysis	_
56-14	9882-9886	were	_
56-15	9887-9891	used	_
56-16	9892-9895	for	_
56-17	9896-9907	statistical	_
56-18	9908-9916	analyses	_
56-19	9917-9918	.	_

Text=Statistical analysis Main analyses of the Neuroimaging Sample were run using SPSS statistical software package (IBM SPSS Statistics ® 20, IBM Corp. ©, Armonk, NY).
57-1	9919-9930	Statistical	_
57-2	9931-9939	analysis	_
57-3	9940-9944	Main	_
57-4	9945-9953	analyses	_
57-5	9954-9956	of	_
57-6	9957-9960	the	_
57-7	9961-9973	Neuroimaging	_
57-8	9974-9980	Sample	_
57-9	9981-9985	were	_
57-10	9986-9989	run	_
57-11	9990-9995	using	_
57-12	9996-10000	SPSS	_
57-13	10001-10012	statistical	_
57-14	10013-10021	software	_
57-15	10022-10029	package	_
57-16	10030-10031	(	_
57-17	10032-10035	IBM	_
57-18	10036-10040	SPSS	_
57-19	10041-10051	Statistics	_
57-20	10052-10053	®	_
57-21	10054-10056	20	_
57-22	10057-10058	,	_
57-23	10059-10062	IBM	_
57-24	10063-10068	Corp.	_
57-25	10069-10070	©	_
57-26	10071-10072	,	_
57-27	10073-10079	Armonk	_
57-28	10080-10081	,	_
57-29	10082-10084	NY	_
57-30	10085-10086	)	_
57-31	10087-10088	.	_

Text=Baseline differences in demographic variables between cases and controls were determined using t-tests for continuous and chi-square tests for categorical variables.
58-1	10089-10097	Baseline	_
58-2	10098-10109	differences	_
58-3	10110-10112	in	_
58-4	10113-10124	demographic	_
58-5	10125-10134	variables	_
58-6	10135-10142	between	_
58-7	10143-10148	cases	_
58-8	10149-10152	and	_
58-9	10153-10161	controls	_
58-10	10162-10166	were	_
58-11	10167-10177	determined	_
58-12	10178-10183	using	_
58-13	10184-10191	t-tests	_
58-14	10192-10195	for	_
58-15	10196-10206	continuous	_
58-16	10207-10210	and	_
58-17	10211-10221	chi-square	_
58-18	10222-10227	tests	_
58-19	10228-10231	for	_
58-20	10232-10243	categorical	_
58-21	10244-10253	variables	_
58-22	10254-10255	.	_

Text=Chi-square tests were performed to test the genotypic distribution of the SNP in both cases and controls.
59-1	10256-10266	Chi-square	_
59-2	10267-10272	tests	_
59-3	10273-10277	were	_
59-4	10278-10287	performed	_
59-5	10288-10290	to	_
59-6	10291-10295	test	_
59-7	10296-10299	the	_
59-8	10300-10309	genotypic	_
59-9	10310-10322	distribution	_
59-10	10323-10325	of	_
59-11	10326-10329	the	_
59-12	10330-10333	SNP	_
59-13	10334-10336	in	_
59-14	10337-10341	both	_
59-15	10342-10347	cases	_
59-16	10348-10351	and	_
59-17	10352-10360	controls	_
59-18	10361-10362	.	_

Text=The primary outcome measure was activation in the caudate, putamen, and nucleus accumbens during reward/loss anticipation as measured by BOLD fMRI.
60-1	10363-10366	The	_
60-2	10367-10374	primary	_
60-3	10375-10382	outcome	_
60-4	10383-10390	measure	_
60-5	10391-10394	was	_
60-6	10395-10405	activation	_
60-7	10406-10408	in	_
60-8	10409-10412	the	_
60-9	10413-10420	caudate	_
60-10	10421-10422	,	_
60-11	10423-10430	putamen	_
60-12	10431-10432	,	_
60-13	10433-10436	and	_
60-14	10437-10444	nucleus	_
60-15	10445-10454	accumbens	_
60-16	10455-10461	during	_
60-17	10462-10473	reward/loss	_
60-18	10474-10486	anticipation	_
60-19	10487-10489	as	_
60-20	10490-10498	measured	_
60-21	10499-10501	by	_
60-22	10502-10506	BOLD	_
60-23	10507-10511	fMRI	_
60-24	10512-10513	.	_

Text=Shapiro-Wilk tests confirmed that all four imaging outcomes (high reward, low reward, high loss, low loss) were normally distributed (all p ≥ 0.407).
61-1	10514-10526	Shapiro-Wilk	_
61-2	10527-10532	tests	_
61-3	10533-10542	confirmed	_
61-4	10543-10547	that	_
61-5	10548-10551	all	_
61-6	10552-10556	four	_
61-7	10557-10564	imaging	_
61-8	10565-10573	outcomes	_
61-9	10574-10575	(	_
61-10	10576-10580	high	_
61-11	10581-10587	reward	_
61-12	10588-10589	,	_
61-13	10590-10593	low	_
61-14	10594-10600	reward	_
61-15	10601-10602	,	_
61-16	10603-10607	high	_
61-17	10608-10612	loss	_
61-18	10613-10614	,	_
61-19	10615-10618	low	_
61-20	10619-10623	loss	_
61-21	10624-10625	)	_
61-22	10626-10630	were	_
61-23	10631-10639	normally	_
61-24	10640-10651	distributed	_
61-25	10652-10653	(	_
61-26	10654-10657	all	_
61-27	10658-10659	p	_
61-28	10660-10661	≥	_
61-29	10662-10667	0.407	_
61-30	10668-10669	)	_
61-31	10670-10671	.	_

Text=For the main analysis of effects of diagnosis, genotype, and their interaction on BOLD responses in the caudate, putamen, and nucleus accumbens, we conducted 2 × 2 analyses of covariance (ANCOVAs) with group (AD vs. HC) T allele carrier status (CC vs. TT/CT–assuming a dominant model) as factors and age, gender, AIM score Europe, and AIM score Africa as covariates.
62-1	10672-10675	For	_
62-2	10676-10679	the	_
62-3	10680-10684	main	_
62-4	10685-10693	analysis	_
62-5	10694-10696	of	_
62-6	10697-10704	effects	_
62-7	10705-10707	of	_
62-8	10708-10717	diagnosis	_
62-9	10718-10719	,	_
62-10	10720-10728	genotype	_
62-11	10729-10730	,	_
62-12	10731-10734	and	_
62-13	10735-10740	their	_
62-14	10741-10752	interaction	_
62-15	10753-10755	on	_
62-16	10756-10760	BOLD	_
62-17	10761-10770	responses	_
62-18	10771-10773	in	_
62-19	10774-10777	the	_
62-20	10778-10785	caudate	_
62-21	10786-10787	,	_
62-22	10788-10795	putamen	_
62-23	10796-10797	,	_
62-24	10798-10801	and	_
62-25	10802-10809	nucleus	_
62-26	10810-10819	accumbens	_
62-27	10820-10821	,	_
62-28	10822-10824	we	_
62-29	10825-10834	conducted	_
62-30	10835-10836	2	_
62-31	10837-10838	×	_
62-32	10839-10840	2	_
62-33	10841-10849	analyses	_
62-34	10850-10852	of	_
62-35	10853-10863	covariance	_
62-36	10864-10865	(	_
62-37	10866-10873	ANCOVAs	_
62-38	10874-10875	)	_
62-39	10876-10880	with	_
62-40	10881-10886	group	_
62-41	10887-10888	(	_
62-42	10889-10891	AD	_
62-43	10892-10895	vs.	_
62-44	10896-10898	HC	_
62-45	10899-10900	)	_
62-46	10901-10902	T	_
62-47	10903-10909	allele	_
62-48	10910-10917	carrier	_
62-49	10918-10924	status	_
62-50	10925-10926	(	_
62-51	10927-10929	CC	_
62-52	10930-10933	vs.	_
62-53	10934-10948	TT/CT–assuming	_
62-54	10949-10950	a	_
62-55	10951-10959	dominant	_
62-56	10960-10965	model	_
62-57	10966-10967	)	_
62-58	10968-10970	as	_
62-59	10971-10978	factors	_
62-60	10979-10982	and	_
62-61	10983-10986	age	_
62-62	10987-10988	,	_
62-63	10989-10995	gender	_
62-64	10996-10997	,	_
62-65	10998-11001	AIM	_
62-66	11002-11007	score	_
62-67	11008-11014	Europe	_
62-68	11015-11016	,	_
62-69	11017-11020	and	_
62-70	11021-11024	AIM	_
62-71	11025-11030	score	_
62-72	11031-11037	Africa	_
62-73	11038-11040	as	_
62-74	11041-11051	covariates	_
62-75	11052-11053	.	_

Text=All tests were two-tailed and considered to be statistically significant at p <0.05.
63-1	11054-11057	All	_
63-2	11058-11063	tests	_
63-3	11064-11068	were	_
63-4	11069-11079	two-tailed	_
63-5	11080-11083	and	_
63-6	11084-11094	considered	_
63-7	11095-11097	to	_
63-8	11098-11100	be	_
63-9	11101-11114	statistically	_
63-10	11115-11126	significant	_
63-11	11127-11129	at	_
63-12	11130-11131	p	_
63-13	11132-11133	<	_
63-14	11134-11138	0.05	_
63-15	11139-11140	.	_

Text=For the NIAAA Sample, minor allele frequency, HWE, and association analyses were conducted using PLINK version 1.07.
64-1	11141-11144	For	_
64-2	11145-11148	the	_
64-3	11149-11154	NIAAA	_
64-4	11155-11161	Sample	_
64-5	11162-11163	,	_
64-6	11164-11169	minor	_
64-7	11170-11176	allele	_
64-8	11177-11186	frequency	_
64-9	11187-11188	,	_
64-10	11189-11192	HWE	_
64-11	11193-11194	,	_
64-12	11195-11198	and	_
64-13	11199-11210	association	_
64-14	11211-11219	analyses	_
64-15	11220-11224	were	_
64-16	11225-11234	conducted	_
64-17	11235-11240	using	_
64-18	11241-11246	PLINK	_
64-19	11247-11254	version	_
64-20	11255-11259	1.07	_
64-21	11260-11261	.	_

Text=Analyses were conducted first in the entire sample, and then separately for EA and AA subgroups, based on self-report.
65-1	11262-11270	Analyses	_
65-2	11271-11275	were	_
65-3	11276-11285	conducted	_
65-4	11286-11291	first	_
65-5	11292-11294	in	_
65-6	11295-11298	the	_
65-7	11299-11305	entire	_
65-8	11306-11312	sample	_
65-9	11313-11314	,	_
65-10	11315-11318	and	_
65-11	11319-11323	then	_
65-12	11324-11334	separately	_
65-13	11335-11338	for	_
65-14	11339-11341	EA	_
65-15	11342-11345	and	_
65-16	11346-11348	AA	_
65-17	11349-11358	subgroups	_
65-18	11359-11360	,	_
65-19	11361-11366	based	_
65-20	11367-11369	on	_
65-21	11370-11381	self-report	_
65-22	11382-11383	.	_

Text=Case-control association with lifetime AD was determined using logistic regression, while association with the MADRS scale was determined using linear regression.
66-1	11384-11396	Case-control	_
66-2	11397-11408	association	_
66-3	11409-11413	with	_
66-4	11414-11422	lifetime	_
66-5	11423-11425	AD	_
66-6	11426-11429	was	_
66-7	11430-11440	determined	_
66-8	11441-11446	using	_
66-9	11447-11455	logistic	_
66-10	11456-11466	regression	_
66-11	11467-11468	,	_
66-12	11469-11474	while	_
66-13	11475-11486	association	_
66-14	11487-11491	with	_
66-15	11492-11495	the	_
66-16	11496-11501	MADRS	_
66-17	11502-11507	scale	_
66-18	11508-11511	was	_
66-19	11512-11522	determined	_
66-20	11523-11528	using	_
66-21	11529-11535	linear	_
66-22	11536-11546	regression	_
66-23	11547-11548	.	_

Text=Both analyses used an additive model and adjusted for age, gender, and AIM scores for European and African ancestry.
67-1	11549-11553	Both	_
67-2	11554-11562	analyses	_
67-3	11563-11567	used	_
67-4	11568-11570	an	_
67-5	11571-11579	additive	_
67-6	11580-11585	model	_
67-7	11586-11589	and	_
67-8	11590-11598	adjusted	_
67-9	11599-11602	for	_
67-10	11603-11606	age	_
67-11	11607-11608	,	_
67-12	11609-11615	gender	_
67-13	11616-11617	,	_
67-14	11618-11621	and	_
67-15	11622-11625	AIM	_
67-16	11626-11632	scores	_
67-17	11633-11636	for	_
67-18	11637-11645	European	_
67-19	11646-11649	and	_
67-20	11650-11657	African	_
67-21	11658-11666	ancestry	_
67-22	11667-11668	.	_

Text=Similarly, for the SAGE Sample, a logistic regression model controlling for age, gender, and 2 PSS for African and European ancestry was performed with the assumption of an additive model.
68-1	11669-11678	Similarly	_
68-2	11679-11680	,	_
68-3	11681-11684	for	_
68-4	11685-11688	the	_
68-5	11689-11693	SAGE	_
68-6	11694-11700	Sample	_
68-7	11701-11702	,	_
68-8	11703-11704	a	_
68-9	11705-11713	logistic	_
68-10	11714-11724	regression	_
68-11	11725-11730	model	_
68-12	11731-11742	controlling	_
68-13	11743-11746	for	_
68-14	11747-11750	age	_
68-15	11751-11752	,	_
68-16	11753-11759	gender	_
68-17	11760-11761	,	_
68-18	11762-11765	and	_
68-19	11766-11767	2	_
68-20	11768-11771	PSS	_
68-21	11772-11775	for	_
68-22	11776-11783	African	_
68-23	11784-11787	and	_
68-24	11788-11796	European	_
68-25	11797-11805	ancestry	_
68-26	11806-11809	was	_
68-27	11810-11819	performed	_
68-28	11820-11824	with	_
68-29	11825-11828	the	_
68-30	11829-11839	assumption	_
68-31	11840-11842	of	_
68-32	11843-11845	an	_
68-33	11846-11854	additive	_
68-34	11855-11860	model	_
68-35	11861-11862	.	_

Text=Analyses were performed separately in individuals of European and African ancestry.
69-1	11863-11871	Analyses	_
69-2	11872-11876	were	_
69-3	11877-11886	performed	_
69-4	11887-11897	separately	_
69-5	11898-11900	in	_
69-6	11901-11912	individuals	_
69-7	11913-11915	of	_
69-8	11916-11924	European	_
69-9	11925-11928	and	_
69-10	11929-11936	African	_
69-11	11937-11945	ancestry	_
69-12	11946-11947	.	_

